Exopharm Ltd
ASX:EX1
Exopharm Ltd
Research & Development
Exopharm Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exopharm Ltd
ASX:EX1
|
Research & Development
-AU$1.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-78%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$60.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Research & Development
-AU$7.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Exopharm Ltd
Glance View
Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.
See Also
What is Exopharm Ltd's Research & Development?
Research & Development
-1.4m
AUD
Based on the financial report for Jun 30, 2023, Exopharm Ltd's Research & Development amounts to -1.4m AUD.
What is Exopharm Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-78%
Over the last year, the Research & Development growth was 44%. The average annual Research & Development growth rates for Exopharm Ltd have been 18% over the past three years , -78% over the past five years .
